SEC Tracker
Get the app

Agios Pharmaceuticals AGIO

David P Schenkein (Director) plans to sell 80,000 AGIO shares, about $2.6M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Feb 23, 2024
  2. Broker: Morgan Stanley Smith Barney LLC - Executive Financial Services
  3. Shares acquired by: Option Exercise

All of David P Schenkein's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 47,731 shares at $33.05 on Feb 23, 2024 · Form 4
  • Sold 20,411 shares at $33.19 on Feb 26, 2024 · Form 4
  • Sold 11,858 shares at $33.6 on Feb 27, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Agios Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  2. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025
  3. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  4. Recursion Pharmaceuticals RXRX public float $2.0B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.